Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

Rhea-AI Summary

Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that Chief Financial Officer Anthony H. Kim will present at the virtual Raymond James Human Health Innovation Conference on June 21, 2021, at 9:20 a.m. ET. Marker Therapeutics is focused on developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. The presentation will be available via a live webcast on their website and can be replayed afterward. The company's innovative approach emphasizes non-engineered, tumor-specific T cells, potentially reducing manufacturing costs and toxicities while enhancing patient outcomes.

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Financial Officer, Anthony H. Kim, will present at the upcoming virtual Raymond James Human Health Innovation Conference on Monday, June 21, 2021 at 9:20 a.m. ET.

A live webcast of the presentation will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-raymond-james-human-health-innovation-conference-301314112.html

SOURCE Marker Therapeutics, Inc.

FAQ

When will Marker Therapeutics present at the Raymond James Human Health Innovation Conference?

Marker Therapeutics, Inc. will present at the Raymond James Human Health Innovation Conference on June 21, 2021, at 9:20 a.m. ET.

Who is presenting for Marker Therapeutics at the conference?

Anthony H. Kim, the Chief Financial Officer of Marker Therapeutics, will present at the conference.

How can I access the live presentation from Marker Therapeutics?

The live presentation by Marker Therapeutics will be accessible through the Investors section of their website.

What is the focus of Marker Therapeutics' research?

Marker Therapeutics specializes in the development of T cell-based immunotherapies for hematological malignancies and solid tumors.

What is unique about Marker Therapeutics' T cell therapy?

Marker Therapeutics' T cell therapy focuses on non-engineered, tumor-specific T cells that target tumor-associated antigens, potentially lowering costs and toxicities.